Last Chance to Get in on This No-Brainer Biotech Trade
Apr 11th, 2008 | By Dr. George Huang | Category: Stock Market InvestingBack in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”